What 5 Analyst Ratings Have To Say About Revance Therapeutics
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) has received 4 bullish and 1 indifferent analyst ratings in the last quarter. The average 12-month price target for the company is $38.6, up 9.5% from the previous average of $35.25.
July 11, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revance Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. In this case, the majority of the ratings are bullish, which indicates a positive outlook for the company. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100